JP2019535263A - 幹細胞由来シュワン細胞を使用する薬物発見のための方法 - Google Patents

幹細胞由来シュワン細胞を使用する薬物発見のための方法 Download PDF

Info

Publication number
JP2019535263A
JP2019535263A JP2019524940A JP2019524940A JP2019535263A JP 2019535263 A JP2019535263 A JP 2019535263A JP 2019524940 A JP2019524940 A JP 2019524940A JP 2019524940 A JP2019524940 A JP 2019524940A JP 2019535263 A JP2019535263 A JP 2019535263A
Authority
JP
Japan
Prior art keywords
days
cells
cell
schwann
differentiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019524940A
Other languages
English (en)
Japanese (ja)
Inventor
ローレンツ スチューダー，
ローレンツ スチューダー，
ファラナク ファタヒ，
ファラナク ファタヒ，
ザニアー ガジザデー，
ザニアー ガジザデー，
シュイビン チェン，
シュイビン チェン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of JP2019535263A publication Critical patent/JP2019535263A/ja
Priority to JP2022022796A priority Critical patent/JP2022059056A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0062—General methods for three-dimensional culture
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
JP2019524940A 2016-11-14 2017-11-14 幹細胞由来シュワン細胞を使用する薬物発見のための方法 Pending JP2019535263A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022022796A JP2022059056A (ja) 2016-11-14 2022-02-17 幹細胞由来シュワン細胞を使用する薬物発見のための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662421816P 2016-11-14 2016-11-14
US62/421,816 2016-11-14
PCT/US2017/061549 WO2018090006A1 (en) 2016-11-14 2017-11-14 Methods for drug discovery using stem cell-derived schwann cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022022796A Division JP2022059056A (ja) 2016-11-14 2022-02-17 幹細胞由来シュワン細胞を使用する薬物発見のための方法

Publications (1)

Publication Number Publication Date
JP2019535263A true JP2019535263A (ja) 2019-12-12

Family

ID=62110088

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019524940A Pending JP2019535263A (ja) 2016-11-14 2017-11-14 幹細胞由来シュワン細胞を使用する薬物発見のための方法
JP2019524951A Pending JP2019535265A (ja) 2016-11-14 2017-11-14 幹細胞由来シュワン細胞
JP2022022796A Pending JP2022059056A (ja) 2016-11-14 2022-02-17 幹細胞由来シュワン細胞を使用する薬物発見のための方法
JP2022072292A Pending JP2022090133A (ja) 2016-11-14 2022-04-26 幹細胞由来シュワン細胞

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019524951A Pending JP2019535265A (ja) 2016-11-14 2017-11-14 幹細胞由来シュワン細胞
JP2022022796A Pending JP2022059056A (ja) 2016-11-14 2022-02-17 幹細胞由来シュワン細胞を使用する薬物発見のための方法
JP2022072292A Pending JP2022090133A (ja) 2016-11-14 2022-04-26 幹細胞由来シュワン細胞

Country Status (9)

Country Link
US (2) US20190264173A1 (enExample)
EP (2) EP3538115A4 (enExample)
JP (4) JP2019535263A (enExample)
KR (1) KR20190077095A (enExample)
CN (2) CN110691601A (enExample)
AU (2) AU2017357072A1 (enExample)
CA (2) CA3043226A1 (enExample)
IL (2) IL266524A (enExample)
WO (2) WO2018090002A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL272246B1 (en) 2017-07-28 2025-09-01 Applied Therapeutics Inc Derivatives of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as aldose reductase inhibitors in treating galactosemia or preventing complications associated with galactosemia
WO2019099902A1 (en) * 2017-11-17 2019-05-23 The Research Foundation for State University of New York A method for treating damaged peripheral nerves using x-ray microbeam irradiation
AU2018379993A1 (en) * 2017-12-04 2020-07-02 Axosim, Inc. Cell systems using spheroids and methods of making and using the same
US11845989B2 (en) 2019-01-23 2023-12-19 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
IL284700B2 (en) 2019-01-23 2025-10-01 Regeneron Pharma Treating eye conditions with angiopoietin-like 7 inhibitors
EP3966320A4 (en) * 2019-05-07 2023-10-25 University of Miami TREATMENT AND DETECTION OF HEREDITARY NEUROPATHIES AND ASSOCIATED DISORDERS
CN110157660A (zh) * 2019-06-10 2019-08-23 西安飞如生物科技有限公司 诱导成纤维细胞分泌抗菌肽的诱导培养基和方法、成纤维细胞及应用
JPWO2021166984A1 (enExample) * 2020-02-20 2021-08-26
EP3929281A1 (en) 2020-06-24 2021-12-29 Fachhochschule Technikum Wien Cell construct comprising schwann cells or schwann cell-like cells and a biocompatible matrix
CA3210480A1 (en) 2021-02-26 2022-09-01 Regeneron Pharmaceuticals, Inc. Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (angptl7) inhibitors
AU2022291933A1 (en) * 2021-06-18 2024-01-18 Memorial Hospital For Cancer And Allied Diseases Methods of generating sacral neural crest lineages and uses thereof
CA3265079A1 (en) * 2022-08-16 2024-02-22 The Regents Of The University Of California CELLULAR COMPOSITIONS AND THEIR METHODS OF USE
WO2025170529A1 (en) 2024-02-09 2025-08-14 Hedlund Eva A method for deriving a multipotent neuromesodermal progenitor cell and/or daughter lineages, and related compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011050379A (ja) * 2009-08-07 2011-03-17 Kyoto Univ イヌｉＰＳ細胞及びその製造方法
WO2011046189A1 (ja) * 2009-10-15 2011-04-21 国立大学法人京都大学 神経変性疾患のモデル細胞、その製造方法及びその用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023568A2 (en) * 1998-10-06 2000-04-27 Albert Einstein College Of Medicine Of Yeshiva University Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells
CN101066472B (zh) * 2007-04-18 2010-05-19 中国人民解放军第二军医大学 组织工程化周围神经移植体及其制备方法
CN102191217A (zh) * 2010-03-12 2011-09-21 上海市第一人民医院 一种诱导脐带间充质干细胞分化为类神经细胞的方法
PT2577318T (pt) 2010-05-25 2019-10-14 Memorial Sloan Kettering Cancer Center Método de diferenciação de nocicetor de células estaminais embrionárias humanas e utilizações do mesmo
CN103429742A (zh) * 2010-10-15 2013-12-04 康奈尔大学 用于治疗内分泌、胃肠或自体免疫性疾病的组合物和方法
JP6133790B2 (ja) * 2011-02-18 2017-05-24 ザ スクリプス リサーチ インスティテュート ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化
EP2614829A1 (en) * 2012-01-11 2013-07-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Mammalian neural plate border stem cells capable of forming neural tube and neural crest cell lineages including central and peripheral neurons
CN105392881B (zh) * 2013-07-23 2020-09-01 豪夫迈·罗氏有限公司 体细胞基于小分子转化为神经嵴细胞
US10323763B2 (en) * 2013-07-30 2019-06-18 Water Technologies Corporation Check valve having polymeric seat and poppet
GB201318126D0 (en) * 2013-10-14 2013-11-27 Univ Cardiff Neuronal Stem Cell Differentiation
JP6723918B2 (ja) 2013-11-21 2020-07-15 メモリアル スローン ケタリング キャンサー センター ヒト多能性幹細胞からの機能的頭蓋プラコード派生体の特定
CN107075504B (zh) * 2014-09-12 2022-02-15 京都府公立大学法人 雪旺氏细胞及其制备方法
US20180140637A1 (en) * 2015-05-19 2018-05-24 Maya Sieber-Blum Epidermal neural crest stem cells as a source of schwann cells
KR101903458B1 (ko) * 2017-01-20 2018-10-02 한국생명공학연구원 슈반 세포 전구체 (Schwann cell precursor) 및 이로부터 분화된 슈반 세포 (Schwann cell)의 제조 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011050379A (ja) * 2009-08-07 2011-03-17 Kyoto Univ イヌｉＰＳ細胞及びその製造方法
WO2011046189A1 (ja) * 2009-10-15 2011-04-21 国立大学法人京都大学 神経変性疾患のモデル細胞、その製造方法及びその用途

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HAO, W., ET AL.: ""Hyperglycemia Promotes Schwann Cell De-differentiation and De-myelination via Sorbitol Accumulation", J. BIOL. CHEM., vol. 290, no. 28, JPN6021042623, 10 July 2015 (2015-07-10), pages 17106 - 17115, ISSN: 0004939028 *
KARIHALOO, A.K., ET AL.: ""Effect of sorbinil and ascorbic acid on myo-inositol transport in cultured rat Schwann cells expose", J. NEUROCHEM., vol. 69, no. 5, JPN6021042617, November 1997 (1997-11-01), pages 2011 - 2018, ISSN: 0004939030 *
LIU, D., ET AL.: ""Effects of High Glucose on Cell Viability and Differentiation in Primary Cultured Schwann Cells: Po", NEUROCHEM. RES., vol. 41, no. 6, JPN6021042622, June 2016 (2016-06-01), pages 1281 - 1290, ISSN: 0004939029 *
MA, MING-SAN, ET AL.: ""Pluripotent Stem Cells for Schwann Cell Engineering."", STEM CELL REVIEWS AND REPORTS, vol. 11, no. 2, JPN6021042613, 2015, pages 205 - 218, ISSN: 0004939031 *
MICA, Y., ET AL.: ""Modeling Neural Crest Induction, Melanocyte Specification, and Disease-Related Pigmentation Defects", CELL REPORTS, vol. 3, no. 4, JPN6021042609, 2013, pages 1140 - 1152, ISSN: 0004624246 *

Also Published As

Publication number Publication date
AU2017357076A1 (en) 2019-05-30
WO2018090002A1 (en) 2018-05-17
IL266524A (en) 2019-07-31
CA3043223A1 (en) 2018-05-17
EP3538115A4 (en) 2020-04-22
JP2022090133A (ja) 2022-06-16
JP2022059056A (ja) 2022-04-12
JP2019535265A (ja) 2019-12-12
EP3538110A4 (en) 2020-04-22
US20190264173A1 (en) 2019-08-29
EP3538110A1 (en) 2019-09-18
US20190331666A1 (en) 2019-10-31
WO2018090006A1 (en) 2018-05-17
AU2017357072A1 (en) 2019-05-30
IL266554A (en) 2019-07-31
CN110249047A (zh) 2019-09-17
KR20190077095A (ko) 2019-07-02
CA3043226A1 (en) 2018-05-17
EP3538115A1 (en) 2019-09-18
CN110691601A (zh) 2020-01-14

Similar Documents

Publication Publication Date Title
JP2022059056A (ja) 幹細胞由来シュワン細胞を使用する薬物発見のための方法
JP7225163B2 (ja) 移植用中脳ドーパミン（ｄａ）ニューロン
CA2920287C (en) Method for producing dopaminergic neurons
KR102679619B1 (ko) 중간뇌 도파민(mda) 뉴런의 시험관내 분화 방법
JP7196376B2 (ja) ヒト人工多能性幹細胞からの皮質ニューロンの分化
US12104169B2 (en) Chemical reprogramming to generate neuronal cells
CN114650836B (zh) 中脑多巴胺神经元的产生和分离方法
US20230233617A1 (en) Methods for differentiating stem cells into dopaminergic progenitor cells
JP7471084B2 (ja) 幹細胞由来星状細胞、作製方法および使用方法
KR20220164012A (ko) 중간뇌 도파민 뉴런의 생성 방법, 중간뇌 뉴런 및 이의 용도
US20240318142A1 (en) Method for producing renal interstitial progenitor cells, erythropoietin-producing cells, and method for producing renin-producing cells
JP2025184905A (ja) 中脳ドーパミンニューロンの生成方法、中脳ニューロンおよびその使用
CN121227633A (zh) 中脑多巴胺神经元的产生和分离方法
HK40075940A (en) Methods of generating and isolating midbrain dopamine neurons

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190712

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220217

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221003

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221003

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20221012

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221027

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221028

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20221209

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20221213